Shares of Guardant Health (NASDAQ: GH) were slipping Friday after investors noticed that one of the company's independent directors sold off some shares. The medical diagnostics provider's stock was down 9.4% as of 1:10 p.m. EDT, washing away the gains produced by the exciting second-quarter earnings report it delivered earlier this month.
Ian Clark was CEO of Genentech from 2010 through 2016, and now he sits on boards of a handful of companies, including Guardant Health. On Monday, Clark sold some shares of Guardant Health at $94.05 immediately after exercising an option that allowed him to acquire them for $4.18 per share.
Image source: Getty Images.